NewsBenzingaPepGen gibt Daten aus seiner Phase-2-Studie FREEDOM2-DM1 zu PGN-EDODM1 bekannt: Die mittlere Spleißkorrektur beträgt 46,5 %; PGN-EDODM1 zeigte eine hohe Verträglichkeit; PepGen gibt Daten aus seiner Phase-2-Studie FREEDOM2-DM1 zu PGN-EDODM1 bekannt: Die mittlere Spleißkorrektur beträgt 46,5 %; PGN-EDODM1 zeigte eine hohe Verträglichkeit; Benzinga 2026.11.10 12:07 (GMT+0) Open on Benzinga Other news Ardent Health Stock Tumbles 14.61% After Hours: Here's Why Lowe's Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Elon Musk Had a Facepalm Moment After Sean Duffy Defends Rejecting Free Starlink for FAA: ‘Our Airspace Is Very Big’ Iridex (NASDAQ: IRIX) Shares Fall 26.96% After Hours: What Investors Should Know ‘The Noise Will Work Itself Out in Time’: AMD CEO Lisa Su Says Nvidia a ‘Phenomenal Company’ After Jensen Huang Exits Morning Bid: Jensen Huang's last hurrah, and a nervy future for Nvidia
Lowe's Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Elon Musk Had a Facepalm Moment After Sean Duffy Defends Rejecting Free Starlink for FAA: ‘Our Airspace Is Very Big’
‘The Noise Will Work Itself Out in Time’: AMD CEO Lisa Su Says Nvidia a ‘Phenomenal Company’ After Jensen Huang Exits